The Lancet Neurology

Along with running dedicated vestibular clinics and working with dizzy patients every day, he also leads a research group focused on the neural mechanisms of balance, dizziness, and multisensory processing.

He's closely involved in classification work for the Barany Society, which is the organization that studies and classifies vestibular disorders, and his research appears in prominent journals like Lancet Neurology, BMJ, and Nature Genetics.

In other words, Dr. Kaski is one of the people at the very top of this field.

He sees the patients everyone else has already seen.

What do I got for you? We're shifting gears, Allie.

I have a paper in Lancet Neurology, which is a fancy.

I think this might be the highest impact journal we've covered on this podcast.

We're getting so fancy.

So I'd love now to focus a bit on the research itself, Olivier, because this is where your work becomes, I think, very concrete, by the way.

[chuckles] Through the Paris Brain Institute, you've helped fund and connect research on ALS at European scale, including Cure ND4ALS, the alliance announced this spring in The Lancet Neurology, uniting the Paris Brain Institute with Germany's DZNE, the UK...

the UK Dementia Research Institute, and the Leuven Brain Institute.

And now you're building a transatlantic collaboration as well between the Paris Brain Institute and Mount Sinai in New York.

And I believe the breakthrough will not come from one country's genius.

It will come from collaboration that is real, not ceremonial.

That is why CureND for ALS matters, uniting Paris with Germany, the United Kingdom, and Belgium, published this spring in the Lancet Neurology, and why we are now building a transatlantic bridge with Mount Sinai in New York.

ALS is the same disease in Paris and in New York.

Periprocedural Antithrombotic Management for Lumber Puncture.

Association of British Neurologists 2026 Guideline Practice Update.

and that's linked to in the show notes there and solomon et al safety and efficacy of adjunct dexamethasone with herpes simplex virus encephalitis uk multi-center observer observer blind randomized phase three control trial and that was lancet neurology 2026 and the cochran review for corticosteroids and acute bacterial meningitis that was matthias brower et al in 2015 and the detailed references for those are all in the show notes okay thank you very much for listening bye

And these been around for, I don't know, like 50 years.

I mean, there's a Lancet Neurology paper where they gave like, you know, I don't know, 20, 30 grams to kids with multiple acyl-CoA deficiency syndrome, like certain inborn errors of metabolism.

And, you know, it's safe.

It helped, you know, save them from cardiomyopathy.

That's really helpful.

So shall we move on then? Let's start with the Canadian study, which was published in the Lancet Neurology paper earlier this year.

What did the researchers do in that study?

This is a really interesting study, and there are also some very similar studies that were done earlier in Wales as well as Australia, and they're all basically saying the same thing.

Of course, a different date of birth cutoff.

Then we have this, as you were mentioning, paper from Canada in the Lancet Neurology published just earlier this year.

Canada is a really nice setting for this research because they actually use two date of birth cutoffs and only in Ontario.

So what you can do is you can look at both date of birth cutoffs

Doctors are finding more unruptured brain aneurysms, even as fewer are actually rupturing.

A Lancet Neurology meta-analysis found the prevalence detected in otherwise healthy people undergoing vascular imaging rose from about 3% to more than 6% over three decades, while aneurysmal subarachnoid hemorrhage fell roughly 40%.

I will cheers to that.

The authors support targeted screening for high-risk groups rather than screening everyone.

Hello and welcome to In Conversation With, a podcast from the Lancet Neurology.

I'm Laura Hart, the Deputy Editor, and this month I'm delighted to be joined by four guests behind our three-part series on future directions in Alzheimer's disease and related disorders.

Clifford Jack from Mayo Clinic, who conceived the series, Charlotte Tunison from Amsterdam University Medical Centre, lead author of the first paper on fluid biomarkers, Tammy Benzinger from Washington University in St. Louis, lead author of the second paper on neuroimaging, and Jonathan Graff-Radford from Mayo Clinic, lead author of the third paper on clinical pathways for cognitively unimpaired people with Alzheimer's disease neuropathological change.

It's been a very thought-provoking discussion.

I hope you've all enjoyed the podcast and thank you for taking the time to talk with us today.

Thank you for listening to this episode of in conversation with the Lancet neurology.

Your host today has been Laura Hart.

This program is part of the Lancet in conversation with series and was produced by Matteo Simonetti.